Introduction: ROS1-rearranged NSCLC is classified as a distinct molecular subset of NSCLC with a therapeutic target. ROS1 rearrangement is most often identified in never-smokers with adenocarcinoma and EGFR and ALK receptor tyrosine kinase gene (ALK) wild type. Treatment with tyrosine kinase inhibitors (TKIs), which target the ROS1 kinase domain, is considered the standard of care. TKIs have been shown to have a robust and durable response. However, information regarding the clinical outcomes of TKI treatment, including brain metastasis, remains limited.
Methods:
We identified 103 consecutive cases of ROS1-positive NSCLC by using break-apart fluorescence in situ hybridization (n ¼ 84), next-generation sequencing (n ¼ 23), or both (n ¼ 3). Information regarding fusion breakpoints was available for eight patients. Clinical data, including patient characteristics, incidence of brain metastasis, response to chemotherapy, or to TKIs, were retrospectively analyzed.
Results: The median patient age was 56 years, and 58.9% of the patients were female. Most of the patients (75.7%) were never-smokers. Adenocarcinoma was predominant (98.1%), and two cases with pleomorphic carcinoma were identified. Sixty percent of patients had an extrathoracic metastatic lesion, and 22% had an intracranial lesion at the initial presentation or at the time of recurrence. The median time to development of brain metastases was 12.0 months (range 2.1-84.1). The most common fusion partner was CD74 molecule gene (CD74), followed by syndecan 4 gene (SDC4), ezrin gene (EZR), tropomyosin 3 gene (TPM3), TRK-fused gene (TFG), zinc finger CCHC-type containing 8 gene (ZCCHC8), sacrolemma associated protein gene (SLMAP), and myosin VC gene (MYO5C). All of these fusion partners preserved the tyrosine kinase domain of ROS1. The median overall survival time was 52.1 months (95% confidence interval [CI]: 23.6-not reached). In the 90 patients who were treated with pemetrexed-based chemotherapy, the overall response rate and progression-free survival time were 53.3% and 8.0 months (95% CI: 6.4-11.7), respectively. The overall response rate and progression-free survival time were 70.7% and 12.7 months (95% CI: 8.1-21.8), respectively, for the 50 patients treated with TKIs. Brain metastasis was more often observed during TKI treatment (15.5%) than during pemetrexed-based chemotherapy (6.7%).
Introduction
ROS1 is a receptor tyrosine kinase of the insulin receptor family. Its rearrangement is recognized as a targetable oncogenic driver that accounts for up to 2% of NSCLCs.
1,2 The ROS1 fusion protein maintains the kinase domain in the 3 0 region of ROS1. It has diverse counterparts, including CD74 molecule, ezrin, syndecan 4, solute carrier family 34 member 2, tropomyosin 3, interleukin 4 induced 1 (also known as FIG1), cell division cycle 6, KDEL endoplasmic reticulum protein retention receptor 2 at 5 0 terminus. 3, 4 Interestingly, the ROS1 and ALK receptor tyrosine kinase (ALK) domains have highly conserved adenosine triphosphate-binding domains, with nearly 77% homology of their amino acid sequences. 5, 6 This structural similarity enables the ALK inhibitor to bind to the ROS1 protein even more strongly than it does to the ALK protein. 6 This phenomenon explains the promising outcomes demonstrated by use of an ALK inhibitor in the treatment of ROS1-rearranged NSCLC. In the PROFILE 1001 study, crizotinib, which is a potent TKI for ALK, ROS1, and mesenchymal-epithelial transition, demonstrated an overall response rate (ORR) of 72%, with a median of 19.2 months of progression-free survival (PFS). 7 Ceritinib, which is a more potent ALK TKI, has demonstrated an ORR of 62% with a PFS of 19.3 months in crizotinib-naive patients. 8 A number of TKIs with ROS1 inhibition are currently in clinical development. [9] [10] [11] On the basis of a few clinical experiences, there have been reports of development of an acquired resistance mechanism after crizotinib therapy in the PROFILE 1001 study. One such mechanism of resistance is ROS1 G2032R in the CD74 molecule-ROS1 fusion protein located at the tyrosine kinase domain. 12 Another characteristic of ROS1-positive NSCLC is a durable response to pemetrexed. Pemetrexed and platinum doublets followed by pemetrexed maintenance therapy has allowed approximately 4 months of PFS in patients with advanced nonsquamous NSCLC with no targetable genomic alterations. 13 In contrast, the same therapy allowed up to 9 months of PFS in ROS1-positive NSCLC. 14,15 ROS1-positive patients have lower expression of thymidylate synthetase (TS) than ROS1-negative patients did; this expression pattern is thought to explain the high efficacy of pemetrexed in ROS1-positive patients.
14 In contrast, patients with ALK-positive NSCLC with similar levels of TS expression have a shorter PFS (range 4.2-7.0 months). 16, 17 Despite the many clinical investigations of TKIs in patients with ROS1-rearranged NSCLC, information regarding its clinical outcomes remain limited. 18, 19 In this study, we have therefore reported the comprehensive analysis of clinical data from ROS1-positive patients in Korea.
Methods

Patients and Samples
We identified 103 patients with NSCLC with ROS1 gene rearrangements who were treated at Samsung Medical Center and Severance Hospital between January 2001 and February 2018. Clinical data, including patient characteristics, the incidence of brain metastasis, and responses to chemotherapy or TKIs, were retrospectively analyzed. Because of local regulation by the health authority, according to which off-label use of chemotherapeutic agents (including targeted agents) in not allowed, TKIs are available only for clinical trials. Hence, the sequence of treatment was decide by the availability of clinical trials. Patients were evaluated for treatment response either by simple chest radiography or chest computed tomography scan. Chest posterior-anterior radiography was performed after every cycle and chest computed tomography was performed after every two or three cycles of treatment. In addition to regular followup, additional imaging was conducted at the physician's discretion. The response rate was calculated by adding the percentage of patients with a partial response and the percentage with a complete response to the treatment. This study was approved by an institutional review board (institutional review board approval No. 2018-04-012-002 and No. 4-2018-0195). Informed consent was waived.
Statistical Analysis
PFS was calculated from the start of treatment to radiographic progression or death. Otherwise, patients were censored from analysis. Overall survival (OS) was defined as the interval from the time of treatment initiation to the date of death. The OS and PFS times were calculated from the initiation of TKI-or pemetrexedbased treatment. To characterize OS on the basis of treatment exposure, we also measured OS from the date of diagnosis to the date of death. Kaplan-Meier curves and risk tables were used to tabulate the treatment failure. The Cox proportional hazard progression model was used to calculate the hazard ratio. Identification of ROS1 Rearrangement ROS1 rearrangement was identified by using fluorescence in situ hybridization (FISH) (POSEIDON ROS1 Dual Color Break Apart Probe, Kreatech, Inc., Amsterdam, the Netherlands) or next-generation sequencing (NGS). As previously described, patients were considered ROS1 positive if there was a split or isolated signal in a kinase domain in at least 15% of tumor cells (after 50 tumor cells were counted in each sample). 1 The internal normal control was identified in the corresponding chromosome targets. A total of 22 samples were sequenced by using the CancerScan panel (LabGenomics, Seongnam, Republic of Korea) to identify the breakpoint of ROS1.
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Results
Clinicopathologic Characteristics of the Study Population
A total of 103 patients with ROS1-positive NSCLC were identified. Most of these patients were female (68.9%) and never-smokers (75.7%). We identified two cases of pleomorphic carcinoma. The remainder of the patients (98.1%) had adenocarcinoma. Interestingly, four patients (4.8%) had EGFR mutations coexisting with their ROS1 rearrangements, as follows: EGFR exon 20 polymorphism c.2361G>A; exon 20 c2319_2320 insertion AACCCCCAC; exon 19 deletion; and exon 21 L833V and L858R. Of the patients, 80 (77.7%) initially presented at an advanced stage. Most patients (93.2%) received palliative chemotherapy, whereas 7.8% patients received definitive concurrent chemoradiotherapy. At their initial presentation, 39.8% of patients had lesions confined to the thorax. As of the time of data lock, 43 patients (41.8%) were alive, 34 (33.0%) had died, and 26 (25.2%) were lost to followup. The median duration of follow-up of the study population was 22.1 months.
The pemetrexed-based regimen included pemetrexed and cisplatin followed by pemetrexed maintenance. This regimen was administered in 87.4% of patients, and TKIs were given to 56.3% of patients. The ROS1 rearrangement was identified by FISH (n ¼ 84), NGS (n ¼ 23), or both (n ¼ 3). A ROS1 breakpoint was identified in 9 of the 23 patients tested by NGS (Table 1) .
Treatment Outcomes
The median OS (calculated from the date of diagnosis to the date of death) for the entire study population was 52.1 months (95% confidence interval [CI]: 23.6-not reached [NR]) (Fig. 1A) . The median OS for patients (Fig. 1B) . Most of the study population was treated with pemetrexed-based chemotherapy (n ¼ 90). However, it was difficult to interpret the actual effect of pemetrexed treatment, especially on OS, because some of the patients (n ¼ 39) also received TKI either before or after the pemetrexed-based chemotherapy. The OS for the patients treated with pemetrexed-based chemotherapy was 54.1 months (95% CI: 24.0-NR) with an HR of 0.55 (95% CI: 0.23-1.31) (Fig. 1C) . The OS in patients treated with pemetrexed but without crossover to a TKI (n ¼ 51) was 60.1 months (95% CI; 25.6-NR) (Fig. 1D) . The median PFS for those treated with a tyrosine kinase inhibitor was 12.7 months (95% CI: 8.1-21.8).
The median OS for those treated with a tyrosine kinase inhibitor was 23.2 months (95% CI: 12.2-NR) ( Fig. 2A  and B) . Of the four different TKIs targeting the ROS1 adenosine triphosphate-binding site, ceritinib had the longest PFS (17.3 months). However, PFS was not reached in the case of TPX-0005, given the short-term follow-up. The PFS for pemetrexed-based therapy was 8.0 months (95% CI: 6.4-11.7) (Fig. 2C) , and the OS for pemetrexed-based therapy was 42.5 months (95% CI: 21.9-NR) (Fig. 2D) .
The ORR for treatment with a TKI was 70.7%, which was higher than the ORR with pemetrexed-based treatment (53.3%). The treatment durations and best responses based on treatment with a TKI are shown in Figure 3 and Table 2 .
Among the patients, there was unique subgroup treated with second TKIs and immune checkpoint inhibitors. Six patients were re-treated with a TKI after failure of treatment with an initial TKI. Of these six patients, one patient showed a partial response to the treatment. However, these patients showed a comparably short PFS (range 1.2-3.4 months) (Supplementary Table 1 ). Twelve patients received immune checkpoint inhibitors, with three of them showing a partial response to the treatment. The PFS of the patients treated with immune checkpoint inhibitors ranged from 1.1 to 10.7 months (Supplementary Table 2 ).
Patterns of Brain Metastases in ROS1-Positive NSCLC
In all, 23 patients (22.3%) had intracranial metastases at the time of their initial diagnosis or at the time of recurrence. Among the 80 patients without brain (Fig. 4) . The most common site of metastasis with pemetrexedbased treatment was intrathoracic; with TKI treatment, the most common form was intracranial progression (15.5%).
ROS1 Breakpoint and TKI Response
NGS was performed for 23 patients. We identified the following fusion partners of ROS1: TRK-fused gene (TFG), tropomyosin 3 gene (TPM3), syndecan 4 gene (SDC4), CD74 molecule gene (CD74), ezrin gene (EZR), zinc finger CCHC-type containing 8 gene (ZCCHC8), sacrolemma associated protein gene (SLMAP), and myosin VC gene (MYO5C) (Fig. 5) . Among eight samples, five had a breakpoint between exons 31 and 33; this breakpoint has little effect in the transmembrane and tyrosine kinase domains of the ROS1 protein. Three samples had a breakpoint at exon 35, which disrupts the structures of the transmembrane domain. However, we did not identify any clinical correlation between the different fusion partners and the TKI treatment outcome (Supplementary Fig. 2 . and Supplementary Table 3) . Resistance developed in one patient who was treated with crizotinib for 32.0 months. Repeat biopsy in the patient demonstrated a G2032R mutation in the CD79 molecule (CD79)-ROS1 fusion gene. This patient subsequently received palliative lorlatinib with partial response.
Discussion
Target therapy and the predictive genomic markers have been shown to be efficacious in patients with EGFR-mutated and ALK-positive NSCLC. The ROS1 gene rearrangement is the third genomic alteration in patients with NSCLC for which TKI therapy has been approved by the U.S. Food and Drug Administration.
In this study, we found that ROS1-positive patients have characteristics similar to those of ALK-positive patients. 21, 22 The patients were mostly female, nonsmokers, and approximately 50 years old. The ROS1 rearrangement is identified predominantly in patients with adenocarcinoma. However, it has a different clinical presentation with regard to tropism. In most patients (60.2%), at least one extrathoracic lesion was present at initial diagnosis. Brain tropism is less prominent in ROS1-positive patients than in patients without this mutation. Only 22.3% of patients presented with brain metastases; however, approximately 30% of patients who did not have intracranial lesions experienced development of brain metastasis during follow-up. Interestingly, intracranial progression was more common in patients treated with a TKI than in those who received chemotherapy. This finding suggests a need to identify novel agents with high penetration of the bloodbrain barrier.
The long duration of PFS with pemetrexed-based treatment is a well-known phenomenon in patients with ROS1 rearrangement. 15, 18, [23] [24] [25] We found that pemetrexed-treated patients (n ¼ 90) had 8.0 months of PFS and 42.5 months of OS from the date of initiation of pemetrexed therapy. These findings were comparable to previous data. The prolonged OS in patients treated with pemetrexed in our data set can be explained by the fact that 81.1% of the population received pemetrexed as the first-line treatment, and 43.3% eventually crossed over to TKI therapy. The OS in patients treated with pemetrexed only is the OS from the date of initiation of pemetrexed therapy for patients treated with pemetrexed without crossover to TKI therapy. This value was still surprising (50.0 months [95% CI: 23.3-NR]); it may be explained by the comparably low level of TS expression in ROS1-positive patients. A similar result was shown in patients with NSCLC who tested negative for TS expression. 14, 26, 27 Overall, this observation suggests that pemetrexed is a treatment option (of cytotoxic chemotherapy) for patients who cannot access TKIs.
We studied four different TKIs in our patient population, namely, crizotinib, ceritinib, TPX-0005, and entrectinib. It is noteworthy that the ORR was at least 65% and the DCR was at least 80% for all four TKIs. However, the median PFS for TKIs in this study (12.7 months) was shorter than the median PFS times of the representative phase 1 crizotinib trial (19.2 months), phase 2 ceritinib trial (19.3 months), and entrectinib studies. 7, 28, 29 Given the small number of patients for each regimen and various lines of therapy, further investigation is needed to evaluate the efficacy of the different agents. As previously described, we identified one case in which a patient acquired resistance to crizotinib as a result of a G2032R mutation. Further studies are needed to determine the mechanisms of resistance to other novel agents and the next optimal treatment options on the basis of the respective mechanisms of resistance.
The most common fusion partner of the ROS1 gene was CD74. This finding was consistent with those of prior studies. However, we also identified the following unique fusion partners of the ROS1 gene that have not been reported previously: ZCCHC8, SLMAP, MYO5C, and TFG. How the ROS1 fusion protein gains its constitutive activation signal is unclear; however, the correlation between clinical efficacy and type of fusion partner has not yet been observed. 7 We also did not find any difference in the clinical outcomes in response to TKIs among the various fusion partners (see Supplementary  Table 3 ). Furthermore, little is known regarding the oncogenicity of the fusion proteins. What is known, however, is that most of the fusion gene does not contain dimerization domains. In addition, the ROS1 kinase domain is always retained in the fusion protein, which was also shown in our eight samples ( Supplementary  Fig. 2 ).
2,5
Our result are very similar to the those reported on the basis of real clinical data rather than on the basis of outcomes of clinical trials. 19 Recently, Gainor et al., 19 reported a pooled analysis of ROS1-positive patients (n ¼ 39) treated in a clinical setting. The ROS1-positive patients had 11.0 months of PFS, which was similar to the 12.7 months of PFS with treatment with a TKI from our data set. We also observed similarity in tropism in the ROS1-positive population to that of those without this mutation. At the time of diagnosis, 19.4% of patients with ROS1 rearrangements had brain metastasis, whereas 59.0% had extrathoracic metastases. These data are very similar to ours, in which 22.3% of ROS1-positive patients had brain metastases and 60.2% had extrathoracic metastases at the time of the initial diagnosis. Once again, our study supports the unique clinical characteristics of ROS1-positive NSCLC represented by tropism in distant metastases. There is no standard method for detecting ROS1 rearrangement. Although FISH is the most common method, it cannot provide information regarding fusion partners. Reverse-transcriptase polymerase chain reaction is another widely used method; however, it can miss unknown fusion genes. ROS1 immunohistochemistry is simple and considered to have high concordance with FISH. It is also difficult to interpret, given the variable location of ROS1 fusions and large amount of background staining. In contrast, NGS can provide detailed information regarding the fusion partners; however, it is limited by its high cost, long turnaround time, and need for a large amout of tissue. 28, 30 There is one reported case of crizotinib being used to treat a patient who was CD74-ROS1-negative according to FISH but CD74-ROS1-positive according to NGS. 31 In contast, in a case of ROS1 positivity according to FISH but ROS1 negativity on the basis of NGS results, the patient had a partial response to first-line pemetrexed but no response to second-line crizotinib. Both of these rare cases reflect the need for careful consideration of ROS1 positivity that is detected with a single method.
This study involved the largest series of clinical data on ROS1-rearranged NSCLC to date; regardless, it does have several limitations. Given the retrospective analysis, this study was subject to potential biases. Because of the low rate of discovery of ROS1 positivity, it was difficult to perform a direct comparison between drugs. Last but not least, the comparison between patients treated with a TKI and then chemotherapy and those treated with chemotherapy and then a TKI has limitations owing to the small number of patients treated with a TKI as first-line treatment (Supplementary Table 4 ).
In conclusion, our data reveal the unique clinical characteristics and outcomes of patients with ROS1-positive NSCLC in Korea. Although ROS1-rearranged NSCLC is rare, it has a robust response to TKIs. Therefore, further efforts are needed to standardize the diagnostic method, develop new therapeutic strategies, and improve patient access.
